Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666525 | 0.88 | POLB (0.31) | POLB | |
| SCHEMBL5778285 | 0.88 | POLB (0.31) | POLB | |
| SCHEMBL25283910 | 0.84 | — | — | |
| SCHEMBL25283978 | 0.84 | — | — | |
| SCHEMBL21827560 | 0.84 | — | — | |
| SCHEMBL25293911 | 0.84 | — | — | |
| SCHEMBL25286243 | 0.84 | — | — | |
| SCHEMBL2538318 | 0.84 | — | — | |
| SCHEMBL20768237 | 0.81 | — | — | |
| SCHEMBL20896665 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| WO-2025122809-A1 | M4 POSITIVE ALLOSTERIC MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-116437917-B | Deuterated derivative of ATX inhibitor and application thereof | 西藏海思科制药有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4149933-B1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2013057101-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-25 | — | — | WO | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2569312-A1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2013-03-20 | — | — | EP | disclosed |
| WO-2013011033-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-24 | — | — | WO | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2012017359-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011141326-A1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20100261699-A1 | N-PYRAZOLE-2-PYRIDINE CARBOXAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| EP-2236507-A1 | N-PYRAZOLE-2-PYRIDINECARBOXAMIDE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | POLB 4802/4885ATM 3611/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | POLB 2944/4885ATM 711/4885 |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ADORA1, CYP3A7, RDX | POLB 1243/4885ATM 3520/4885 |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | POLB 2199/4885ATM 935/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | POLB 2902/4885ATM 710/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | POLB 3653/4885ATM 921/4885 |
| US-20100261699-A1 | N-PYRAZOLE-2-PYRIDINE CARBOXAMIDE DERIVATIVE | GCKR, GPR119, GCK | POLB 4274/4885ATM 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.